All News
Key take home points from @_AprilArmstrong on psoriatic disease @RheumNow #RNL2024 https://t.co/Svx9gNKBuR
Richard Conway RichardPAConway ( View Tweet)
Potential board question: be able to differentiate between osteitis condensan ilii vs sacroiliitis. With osteitis condensan, the SI joint is normal, with no irregularity, erosions, or loss of joint space. Sclerosis is predominantly on the iliac bone @rheumnow #RNL2024 @rheumnow https://t.co/mimcdoufEE
TheDaoIndex KDAO2011 ( View Tweet)
Men with PsA have more severe psoriasis, axial disease, high CRP, erosive disease compared to women, but women tend to have more pain. Delay to diagnosis in female patients are likely related to these differences- Dr. Eder #RNL2024 @rheumnow https://t.co/S9dzANITfH
TheDaoIndex KDAO2011 ( View Tweet)
Nice summary of data as to why IL-17 or IL-23 are generally favoured by dermatology for psoriasis @_AprilArmstrong @RheumNow #RNL2024 https://t.co/qfAn2AHilX
Richard Conway RichardPAConway ( View Tweet)
Dr. Eder on gender differences – we need to move from gender blind to gender specific approach to treating our patients. There are biological, cultural, and social differences between males and females. #RNL2024 @rheumnow https://t.co/gnzU6FKIPR
TheDaoIndex KDAO2011 ( View Tweet)
Key takeaways when choosing therapies anti-TNFs, IL-17i, IL-23i, JAKs and TYK-2, in psoriasis. Think of skin, joint and spine involvement, April Armstrong #RNL2024 @RheumNow https://t.co/nUMmQk4xZq
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Considerations in choosing a biologic in psoriatic disease from dermatology viewpoint @_AprilArmstrong @RheumNow #RNL2024 https://t.co/PHg0CBjTkC
Richard Conway RichardPAConway ( View Tweet)
#RNL2024 @RheumNow
@_AprilArmstrong: Deucravacitinib v Apremilast
Deucra: TYK2 inhibitor, approved for PsO (not yet PsA)
Superior to apremilast for skin disease (sPGA) https://t.co/NRnsm4cOum
Eric Dein ericdeinmd ( View Tweet)
Dr. A. Armstrong's Key Takeaways for PsO.
TNFi - great in PsA and pregnancy
IL-17i - robust PsO efficacy and in PsA
IL-23i - robust in PsO, fewer injections, and efficacious in PsA.
#RNL2024 @RheumNow @_AprilArmstrong https://t.co/j8LaOGITuf
Dr. Rachel Tate uptoTate ( View Tweet)
Did you know of all the small oral molecules, #apremilast is the only one approved for all stages of #psoriasis (mild to severe)? - Dr. Armstrong polls the audience on their thoughts then revealing the correct answer #RNL2024 @rheumnow https://t.co/NXSiaaGp3p
TheDaoIndex KDAO2011 ( View Tweet)
Dr. A. Armstrong shares dermatology/dermatologist trends in PsO.
1. They tend to shorted then interval between injections as opposed to the amount of medication per dose.
2. Derms generally wait 6 months to switch meds
3. Like rheums, derms tend to switch classes (of tx agent)… https://t.co/HWbJMwnwkE https://t.co/bgKw7ynANN
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
How are dermatology colleagues may frame our treatment options @_AprilArmstrong . This is helpful to consider in light of shared care discussions. The lack of love for JAKi in particular. @RheumNow #RNL2024 https://t.co/pv5EFXsXjI
Richard Conway RichardPAConway ( View Tweet)
When it comes to skin, this is how derms think and there is data to support this. - Dr. Amstrong on how IL-17i and IL23i are preferred over TNFi #psoriasis #RNL2024 @rheumnow https://t.co/UZWNgOljRh
TheDaoIndex KDAO2011 ( View Tweet)
Welcome to the "FDA-approved" team Bimekizumab. Dr. Armstrong shows MOA of IL17a and IL17f dual inhibition, and the important PASI scores showing 2/3 of pts clear by week 16. @RheumNow #RNL2024 https://t.co/5ygHgOTfW8
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Dermatologic approach to choosing treatment in psoriatic disease. The presence of psoriatic arthritis is an initial branch point and why co-management is so crucial in these patients @_AprilArmstrong @RheumNow #RNL2024 https://t.co/m26WiEUmPI
Richard Conway RichardPAConway ( View Tweet)
#RNL2024 @RheumNow
@_AprilArmstrong
Bimekizumab: IL-17A and IL-17F dual efficacy, unlike the prior IL-17i drugs
- Fast onset
- High efficacy with 2/3 PASI 100 by wk 16 (BE READY) https://t.co/cKh7j4KBs9
Eric Dein ericdeinmd ( View Tweet)
"We are setting a new standard for the skin, PASI100" -Dr. A Armstrong on the goal of treatment for #psoriasis. #TigerMom @rheumnow #RNL2024
TheDaoIndex KDAO2011 ( View Tweet)
In a patient with purely skin limited plaque psoriasis without systemic involvement, what would you choose for treatment? The rheum audience poll at #RNL2024 is all over the place in their choice! Dr. Armstrong lectures on how derms think about #psoriasis @rheumnow https://t.co/4YxaJPlpa5
TheDaoIndex KDAO2011 ( View Tweet)
#RNL2024 @RheumNow
@_AprilArmstrong
Choosing a biologic in Psoriasis
TNF - great in PsA, pregnancy. Avoid in demyelinating, hep B
IL-17 - robust skin, PsA (axial too). Avoid in IBD
IL-23 - robust skin, PsA evidence, fewer injections https://t.co/9Xt7Nx1tKq
Eric Dein ericdeinmd ( View Tweet)
Dr. April Armstrong shares a beautiful picture around pathophysiology in PsO/PsA, as demonstrated in a non-joint graphic below. "Consider the domains when choosing biologics." #RNL2024 @RheumNow https://t.co/4AtbEhysyA
Dr. Rachel Tate uptoTate ( View Tweet)